Cargando…

State of the art: Oral antiplatelet therapy

Platelet adhesion, activation, and aggregation are central to the propagation of coronary thrombosis following rupture, fissure, or erosion of an atherosclerotic plaque. This chain of deleterious events underlies the pathophysiological process leading to an acute coronary syndrome. Therefore, oral a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurbel, Paul A, Myat, Aung, Kubica, Jacek, Tantry, Udaya S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892624/ https://www.ncbi.nlm.nih.gov/pubmed/27298725 http://dx.doi.org/10.1177/2048004016652514

Ejemplares similares

Personalized antiplatelet therapy: state of the art
por: Gurbel, Paul A, et al.
Publicado: (2012)

Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus
por: Jung, Jung Hwa, et al.
Publicado: (2015)

Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing
por: Jeong, Young-Hoon, et al.
Publicado: (2019)

Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent
por: Tantry, Udaya S, et al.
Publicado: (2021)

In Vitro Evidence for the Role of Cytokine Storm in the Generation of Stent Thrombosis in COVID-19 Patients
por: Gurbel, Paul A., et al.
Publicado: (2022)

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
por: Gurbel, Paul A, et al.
Publicado: (2010)

International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests
por: Gurbel, Paul A., et al.
Publicado: (2021)

Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
por: Gurbel, Paul A., et al.
Publicado: (2018)

Further evidence for the use of aspirin in COVID-19
por: Tantry, Udaya S., et al.
Publicado: (2022)

Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can “Thrombin Pathway” Be a New Target for Therapy?
por: Kim, Hyun Kuk, et al.
Publicado: (2020)

High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells
por: Grześk, Grzegorz, et al.
Publicado: (2013)

Antiplatelet therapy in secondary stroke prevention – state of the art
por: Diener, Hans-Christoph, et al.
Publicado: (2010)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

IS THERE A ROLE FOR α1-ANTITRYPSIN IN COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

AGE-BASED RISK FACTORS FOR SYMPTOMATIC COVID-19 IN THE MINORITY POPULATION
por: Gurbel, Paul A., et al.
Publicado: (2021)

Personalized antiplatelet therapy with P2Y(12) receptor inhibitors: benefits and pitfalls
por: Winter, Max-Paul, et al.
Publicado: (2015)

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
por: Ostrowska, Małgorzata, et al.
Publicado: (2019)

Relationship of Platelet Reactivity With Bleeding Outcomes During Long‐Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non‐ST‐Segment Elevation Acute Coronary Syndromes
por: Cornel, Jan H., et al.
Publicado: (2016)

Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2012)

Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues
por: Verdoia, Monica, et al.
Publicado: (2020)

Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population
por: Gurbel, Paul A., et al.
Publicado: (2021)

IS LOW DOSE ASPIRIN EFFECTIVE IN REDUCING IN-HOSPITAL CLINICAL OUTCOMES IN PATIENTS WITH COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences
por: Kim, Hyun Kuk, et al.
Publicado: (2021)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice
por: Tubek, Stanisław, et al.
Publicado: (2021)

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
por: Navarese, Eliano P., et al.
Publicado: (2023)

Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations
por: Chaudhary, Rahul, et al.
Publicado: (2020)

Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial
por: Park, Hyun-Woong, et al.
Publicado: (2021)

Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
por: Hillegass, William B, et al.
Publicado: (2011)

Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
por: Zeymer, Uwe
Publicado: (2013)

Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease Patients
por: Lev, Eli I., et al.
Publicado: (2014)

Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
por: Berger, Jeffrey S.
Publicado: (2018)

Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review
por: Showkathali, Refai, et al.
Publicado: (2012)

Oral Appliance Therapy for Obstructive Sleep Apnoea: State of the Art
por: Sutherland, Kate, et al.
Publicado: (2019)

Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes
por: Usman, Abira, et al.
Publicado: (2022)

Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options
por: Fintel, Dan J
Publicado: (2012)

Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events
por: De Luca, Leonardo, et al.
Publicado: (2021)

First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19
por: Tantry, Udaya S, et al.
Publicado: (2021)

Precision antiplatelet therapy
por: Rocca, Bianca, et al.
Publicado: (2023)

Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens
por: Heramvand, Nadia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3k97m4lt58qbilntml8j9qbnfv